Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}

Dr. Kotzbauer obtained his MD and PhD degrees from Washington University School of Medicine. He completed clinical training in neurology and movement disorders, as well as further research training in neurodegenerative disorders, at the University of Pennsylvania. He is currently an associate professor of neurology at Washington University School of Medicine, where he devotes time to both laboratory research and patient care. His research focuses on disease mechanisms and the development of improved diagnostic and therapeutic approaches in Parkinson's disease (PD) as well as a group of hereditary neurological disorders known as neurodegeneration with brain iron accumulation. Ongoing PD research in his lab seeks to understand mechanisms of misfolded alpha-synuclein protein accumulation, to identify ways to monitor misfolded alpha-synuclein as a biomarker for PD progression, and to identify methods to block its accumulation as a therapeutic approach in PD.